CA2702635A1 - A new biomarker for monitoring development of diseases and assessing the efficacy of therapies - Google Patents

A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Download PDF

Info

Publication number
CA2702635A1
CA2702635A1 CA2702635A CA2702635A CA2702635A1 CA 2702635 A1 CA2702635 A1 CA 2702635A1 CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A CA2702635 A CA 2702635A CA 2702635 A1 CA2702635 A1 CA 2702635A1
Authority
CA
Canada
Prior art keywords
disease
sample
protein
patient
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2702635A
Other languages
English (en)
French (fr)
Inventor
Sirpa Jalkanen
Marko Salmi
Markku Jalkanen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Faron Pharmaceuticals Oy
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2702635A1 publication Critical patent/CA2702635A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
CA2702635A 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies Abandoned CA2702635A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20070795 2007-10-24
FI20070795A FI20070795A0 (fi) 2007-10-24 2007-10-24 Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
PCT/FI2008/050576 WO2009053523A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Publications (1)

Publication Number Publication Date
CA2702635A1 true CA2702635A1 (en) 2009-04-30

Family

ID=38656804

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2702635A Abandoned CA2702635A1 (en) 2007-10-24 2008-10-15 A new biomarker for monitoring development of diseases and assessing the efficacy of therapies

Country Status (14)

Country Link
US (1) US20100209942A1 (enExample)
EP (2) EP2201376B1 (enExample)
JP (2) JP4982610B2 (enExample)
KR (2) KR20160029869A (enExample)
CA (1) CA2702635A1 (enExample)
CY (2) CY1113403T1 (enExample)
DK (2) DK2201376T3 (enExample)
ES (2) ES2532361T3 (enExample)
FI (1) FI20070795A0 (enExample)
HR (2) HRP20120743T1 (enExample)
PL (2) PL2201376T3 (enExample)
PT (2) PT2201376E (enExample)
SI (2) SI2201376T1 (enExample)
WO (1) WO2009053523A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201704689XA (en) 2008-01-18 2017-07-28 Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
CA2806301A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting cardiovascular diseases or conditions
CA2806304A1 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
MX2013000917A (es) 2010-07-23 2013-07-05 Harvard College Metodos para detectar las enfermedades o condiciones usando celulas fagociticas.
EA201590024A1 (ru) 2012-06-15 2015-05-29 Гарри Стилли Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
CN104603289A (zh) 2012-06-15 2015-05-06 哈里·斯泰利 检测疾病或病状的方法
PL2956772T3 (pl) * 2013-02-14 2018-12-31 Faron Pharmaceuticals Oy Sposób określenia biomarkerów związanych z zespołem ostrej niewydolności oddechowej (ARDS), sposób monitorowania rozwoju i leczenia ARDS u pacjenta
WO2014164362A1 (en) 2013-03-09 2014-10-09 Harry Stylli Methods of detecting prostate cancer
NZ771629A (en) 2013-03-09 2022-12-23 Harry Stylli Methods of detecting cancer
EP4428251A3 (en) 2014-09-11 2024-12-18 Immunis.AI, Inc. Methods of detecting prostate cancer
ES2826566T3 (es) 2014-11-21 2021-05-18 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas
JP6805142B2 (ja) 2014-11-21 2020-12-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｄ７３に対する抗体およびその使用
GB201706747D0 (en) 2017-04-27 2017-06-14 Queen Mary Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients
GB201715115D0 (en) 2017-09-19 2017-11-01 Univ London Queen Mary Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997007236A1 (en) * 1995-08-18 1997-02-27 Landry Donald W Detection of organic compounds through regulation of antibody-catalyzed reactions
WO1997013875A1 (en) 1995-10-13 1997-04-17 Imperial College Of Science, Technology & Medicine Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy
HUP0002003A3 (en) 2000-05-24 2003-01-28 Pronuk Biotechnologia Kft Process and reagent-kit for determining of 5'-nucleotidase activity
CA2439961A1 (en) * 2001-03-27 2002-10-03 Zymogenetics, Inc. Human cytokine receptor
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
US7534423B2 (en) * 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
FI20030467A0 (fi) * 2003-03-28 2003-03-28 Sirpa Jalkanen Menetelmä tulehdustilojen hoitamiseen
CA2528152A1 (en) * 2003-06-03 2005-01-06 The Regents Of The University Of California Compositions and methods for treatment of disease with acetylated disaccharides
WO2007025044A2 (en) * 2005-08-24 2007-03-01 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
WO2007107598A1 (en) * 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
EP3796002B1 (en) * 2006-07-14 2023-11-22 The Regents of The University of California Cancer biomarkers and methods of use thereof

Also Published As

Publication number Publication date
KR20100059902A (ko) 2010-06-04
JP2012159514A (ja) 2012-08-23
CY1113403T1 (el) 2016-06-22
ES2389751T3 (es) 2012-10-31
PL2201376T3 (pl) 2013-01-31
EP2201376A1 (en) 2010-06-30
DK2503338T3 (en) 2015-03-09
PT2503338E (pt) 2015-03-05
JP4982610B2 (ja) 2012-07-25
EP2503338A3 (en) 2013-03-13
EP2201376B1 (en) 2012-08-08
PT2201376E (pt) 2012-08-20
CY1116089T1 (el) 2017-02-08
JP2011501176A (ja) 2011-01-06
SI2503338T1 (sl) 2015-06-30
EP2503338B1 (en) 2014-12-24
KR20160029869A (ko) 2016-03-15
US20100209942A1 (en) 2010-08-19
HRP20150181T1 (hr) 2015-06-19
ES2532361T3 (es) 2015-03-26
EP2503338A2 (en) 2012-09-26
HRP20120743T1 (hr) 2012-10-31
PL2503338T3 (pl) 2015-06-30
SI2201376T1 (sl) 2012-09-28
EP2201376A4 (en) 2011-03-23
FI20070795A0 (fi) 2007-10-24
DK2201376T3 (da) 2012-10-15
JP5619810B2 (ja) 2014-11-05
WO2009053523A1 (en) 2009-04-30

Similar Documents

Publication Publication Date Title
EP2201376B1 (en) A new biomarker for monitoring development of diseases and assessing the efficacy of therapies
US8975081B2 (en) Biomarker for monitoring development of diseases and assessing the efficacy of therapies
Chaiworapongsa et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia: Young Investigator Award
Shipe et al. Number, activation, and differentiation of circulating fibrocytes correlate with asthma severity
Cha et al. Tumor necrosis factor-alpha induces vascular endothelial growth factor-C expression in rheumatoid synoviocytes.
Alturaiki et al. Assessment of IL‐1β, IL‐6, TNF‐α, IL‐8, and CCL 5 levels in newly diagnosed Saudi patients with rheumatoid arthritis
JP2010519898A (ja) ライノウイルス感染を制御するための化合物の同定方法及び標的
US20090011444A1 (en) Detection and diagnosis of inflammatory disorders
Obiefuna et al. A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)-ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3, 7-dihydro-purine-2, 6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma
KR20190039089A (ko) 결장직장암에 대한 복합 테스트
Koczulla et al. Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients
Engebretsen et al. Acute hypobaric hypoxia (5486 m) induces greater pulmonary HIF-1 activation in hilltop compared to madison rats
Gatselis et al. Calprotectin serum levels on admission and during follow-up predict severity and outcome of patients with COVID-19: A prospective study
CN111094981B (zh) Pct和pro-adm作为监测抗生素治疗的标记物
CN116801788A (zh) 用于评估肝脏疾病的试剂盒、试剂和方法
Dutta et al. Diagnosis of infected pancreatic necrosis: A review of the role of blood biomarkers
CN110678757B (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
WO2011125858A1 (ja) バイオマーカー
Salam et al. Assessment of serum interleukin-20 and interleukin-33 levels in rheumatoid arthritis patients
Sumi et al. Regional variations in allergen-induced airway inflammation corresponds to changes in soluble guanylyl cyclase heme and expression of heme-oxygenase-1
CN117529664A (zh) 用于预测脓毒症和脓毒性休克的方法
Jedynak et al. Serum concentrations of MCP-1 and RANTES in patients during aortic surgery: the relationship with ischemia-reperfusion
Kato et al. Neutrophil gelatinase-associated lipocalin in patients with sarcoidosis
KR20220031084A (ko) 표피 성장 인자 수용체 저해제에 의해 야기되는 피부 약물 부작용의 위험성 평가 방법, 이의 검출 키트 및 이의 용도
Sandström et al. Endotoxin receptor CD14 in PiZ α-1-antitrypsin deficiency individuals

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130827

FZDE Discontinued

Effective date: 20201005